QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Meningococcal Group B Vaccine (Recombinant) Pharmacovigilance

Test your understanding of the concepts covered by Meningococcal Group B Vaccine (Recombinant): fHbp Biology, Immunisation and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement most accurately characterises the protection model for this vaccine?

Protection depends only on the concentration of total antibody, regardless of antibody function Protection is expected to involve functional antibodies capable of supporting killing of susceptible meningococci with complement Protection is based primarily on vaccine replication in the nasopharynx Protection requires antibodies against the serogroup B capsule in every vaccinated individual

Question 2 of 10 Which pharmacovigilance governance practice is most consistent with the article's recommendations for patients receiving complement inhibitors?

Assess vaccination as an isolated exposure and omit treatment history Integrate complement-inhibitor use, underlying susceptibility, vaccination history and relevant preventive measures into the case assessment Exclude such cases from safety databases because the drug is the likely cause Classify every infection in these patients as an administration error

Question 3 of 10 Which conclusion is best supported when a vaccinated patient develops confirmed non-B meningococcal disease?

The case is automatically evidence of failure to prevent serogroup B disease The disease should be distinguished from serogroup B breakthrough because the vaccine's stated target is serogroup B The patient must have received the wrong route of administration The vaccine cannot generate bactericidal antibodies

Question 4 of 10 What is the most appropriate role of public-health laboratories in the pharmacovigilance framework described?

They replace spontaneous reporting for all vaccine-related events They may provide serogroup, strain and fHbp information that strengthens investigation of invasive breakthrough disease They determine whether an injection-site reaction was painful They establish the authorised age range in every jurisdiction

Question 5 of 10 Why should a post-vaccination faint not automatically be interpreted as an antigen-specific adverse reaction?

Syncope cannot occur in adolescents The injection procedure and situational factors may contribute independently of the antigen All post-vaccination events are unrelated to vaccination Syncope is proof of successful bactericidal immunity

Question 6 of 10 A report describes a patient as 'fully vaccinated' but gives no dates for prior doses. What is the most appropriate pharmacovigilance response?

Accept the description because dose dates are not relevant once vaccination is complete Obtain every dose date and compare the actual history with the schedule applicable in that setting Assume the patient followed the schedule in the European Union Classify the case automatically as a vaccination failure

Question 7 of 10 Why is confirmation of the infecting meningococcal serogroup essential in a suspected breakthrough case?

The vaccine is intended to prevent every bacterial infection regardless of serogroup Disease caused by a non-B serogroup should not be interpreted as failure of a vaccine specifically targeting serogroup B disease Serogroup determines whether the patient experienced syncope Serogroup confirmation replaces the need to document vaccination dates

Question 8 of 10 Which finding would most strongly support a clinically meaningful assessment of suspected immediate hypersensitivity?

A large local reaction with no systemic findings Objective respiratory or cardiovascular compromise, treatment details and a compatible post-injection chronology Mild fatigue beginning several days after vaccination A report that the patient disliked the injection

Question 9 of 10 What is the principal antigenic strategy of the recombinant meningococcal group B vaccine described in the article?

Use of a live attenuated serogroup B meningococcus Use of two lipidated fHbp variants representing subfamilies A and B Use of purified serogroup B capsular polysaccharide alone Use of meningococcal outer-membrane vesicles containing all surface antigens

Question 10 of 10 Why does inclusion of fHbp variants from subfamilies A and B potentially broaden vaccine-induced recognition?

It ensures that every serogroup B strain expresses identical fHbp It exposes the immune system to antigenic representatives from two major fHbp subfamilies It eliminates the need for complement-mediated antibody activity It provides direct immunity against all meningococcal serogroups

Knowledge Assessment: Meningococcal Group B Vaccine (Recombinant) Pharmacovigilance

Cookie Settings